Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations

Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations

Background: Given advancements in adjuvant treatments for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)-targeted therapies, it is important to consider postoperative targeted therapies for other early-stage oncogene-addicted NSCL...

Full description

Bibliographic Details
Main Authors: Nadia Ghazali, Jamie Feng, Katrina Hueniken, Khaleeq Khan, Karmugi Balaratnam, Thomas K. Waddell, Kazuhiro Yasufuku, Andrew Pierre, Laura Donahoe, Elliot Wakeam, Marcelo Cypel, Jonathan Yeung, Shaf Keshavjee, Marc de Perrot, Natasha B. Leighl, Geoffrey Liu, Penelope A. Bradbury, Adrian Sacher, Lawson Eng, Tracy Stockley, Ming Sound Tsao, Frances A. Shepherd
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241308466

Internet

https://doi.org/10.1177/17588359241308466

Similar Items